leukemia / tumor / HER2-positive human cancer / cancer / tumors / triple-negative breast cancer / blood cancers / drug-resistant HER2-positive breast cancer / different HER2-positive breast cancer / drugresistant HER2-positive breast cancer / HER2-positive breast cancer / breast cancer / different ways HER2-positive cancer / human HER2-positive breast cancer / /
Organization
FDA / UNC School of Medicine Resistance / UNC School of Medicine / University of North Carolina / UNC Lineberger Comprehensive Cancer Center / University of North Carolina Health Care / /
Person
Tim Stuhlmiller / Gary Johnson / /
Position
senior author / first author / Professor and chair of the department / /